PHARMING GRP SP. ADRS Working Capital to Net Assets Ratio
PHARMING GRP SP. ADRS working capital to net assets ratio. PHARMING GRP SP. ADRS (PHG) has a Working Capital to Net Assets ratio of 66.3% as of December 2025. Working capital of €183.68 Million (current assets of €299.47 Million minus current liabilities of €115.79 Million) is measured against net assets of €277.10 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of PHARMING GRP SP. ADRS (2021–2025)
Working capital to net assets ratio of PHARMING GRP SP. ADRS from 2021 to 2025. This chart shows how PHARMING GRP SP. ADRS's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 66.3%, reflecting working capital of €183.68 Million against net assets of €277.10 Million EUR. Explore PHARMING GRP SP. ADRS strategic investment ratio to see how much of total assets are deployed in long-term investments.
PHARMING GRP SP. ADRS Working Capital to Net Assets Ratio by Year (2021–2025)
PHARMING GRP SP. ADRS working capital to net assets ratio by year from 2021 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for PHARMING GRP SP. ADRS from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see PHARMING GRP SP. ADRS total assets.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 66.3% | €183.68 Million | €277.10 Million | €299.47 Million | €115.79 Million | ▼ -26.3 pp |
| 2024 | 92.6% | €204.64 Million | €221.06 Million | €278.44 Million | €73.80 Million | ▼ -16.4 pp |
| 2023 | 109.0% | €238.37 Million | €218.78 Million | €316.34 Million | €77.97 Million | ▲ +2.5 pp |
| 2022 | 106.4% | €217.80 Million | €204.64 Million | €277.50 Million | €59.70 Million | ▲ +1.4 pp |
| 2021 | 105.1% | €202.67 Million | €192.92 Million | €249.44 Million | €46.77 Million | — |